The firm is a private investment firm based in Asia, supported by a major scientific research institution and led by professionals with combined experience in R&D, entrepreneurship, and investment across both Asia and the United States. The firm invests in early-stage life sciences and healthcare companies, with typical allocation sizes ranging from approximately $0.5M to $5M. The firm is open to both leading and participating in financing rounds and evaluates opportunities across China and the United States.
The firm invests broadly across life sciences sectors, including biopharmaceuticals, medical devices, diagnostics, life science R&D services, and healthcare services. The firm has a particular interest in clinical-stage molecular diagnostics and shows comparatively less interest in very early-stage projects, though it remains open to select preclinical opportunities. The firm is disease-agnostic.
From a company and management team perspective, the firm seeks experienced teams with validated products or technologies. The firm can provide strategic support for regulatory approval and commercialization in China by leveraging a network that includes pharmaceutical partners, CROs and CMOs, academic institutions, and distribution channels. The firm may also seek distribution rights in China and consider board representation on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment